Avalo Therapeutics, Inc. aksje
AVTX
After-hours$13.96-1.79 (-11.37%)
Post-Market:$14.23+0.27 (+1.93%)
Laster graf...
Avalo Therapeutics, Inc.
Market Cap
$733,815,360
Åpning15.44
Høy15.62
Lav13.78
Volum1.6M
P/EN/A
Markedsverdi733.82M
52-ukers høy24.27
52-ukers lav4.06
Gj.sn. volum1.48M
UtbytteN/A
Beta0.79
EPS-5.57
Om Avalo Therapeutics, Inc. aksje
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Selskapsinformasjon
Børs: NasdaqCM (NCM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
1500 Liberty Ridge Drive
19087 Wayne, United States
19087 Wayne, United States
Telefon: + 410 522 8707
Nettside: https://www.avalotx.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Laveste kursmål
34.00
↑ 143.6%
Gjennomsnittlig kursmål
46.18
↑ 230.8%
Median kursmål
45.00
↑ 222.3%
Høyeste kursmål
60.00
↑ 329.8%